SR-4835 是有效，高选择性和 ATP 竞争性的 CDK12/CDK13 双重抑制剂 (CDK12:IC50=99 nM，Kd=98 nM；CDK13:Kd=4.9 nM)。SR-4835 与破坏 DNA 的化学疗法和 PARP 抑制剂协同作用，并引起三阴性乳腺癌 (TNBC) 细胞凋亡。
货号:ajcx16126
CAS:2387704-62-1
分子式:C21H20Cl2N10O
分子量：499.36
溶解度:DMSO: 5 mg/mL (10.01 mM; ultrasonic and warming and heat to 60°C)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death[1].

[1]. Quereda V, et al. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. Cancer Cell. 2019 Oct 8. pii: S1535-6108(19)30424-6.